Advagene Biopharma Patent for Asthma Treatment Using Detoxified E. coli Labile Toxin

USPTO published patent application US20260098065A1 assigned to Advagene Biopharma Co., Ltd. covering a method for treating eosinophil-associated inflammation such as severe asthma using a therapeutically effective amount of a composition comprising detoxified Escherichia coli labile toxin for mucosal administration. The application names Han-Pin KUO, Yu-Shen HSU, Ming-I CHANG, and Yi-Shiuh HWANG as inventors, with filing date 2025-09-26 and application number 19341203.\n\nPharmaceutical companies, drug manufacturers, and biotech firms developing inflammation or asthma therapeutics should monitor this published application to assess potential freedom-to-operate implications or partnership opportunities. The CPC classifications C07K 14/245 (E. coli peptides), A61P 11/06 (anti-asthmatics), and A61K 38/00 (peptides as pharmaceuticals) indicate the scope of the disclosed invention.